Video

Dr. Mehra Discusses DNA Repair Enzymes

Author(s):

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes

Ranee Mehra, MD, Medical Oncology, head and neck care team, lung cancer care team, Fox Chase Cancer Center, discusses the use of DNA repair enzymes, such as ERCC1, as predictive markers for resistance and survival in head and neck cancer patients.

Mehra explains that in a retrospective tumor sample analysis of patient that had received induction regimens follow by radiation or concurrent chemo radiation there was a clear trend towards improved response and survival outcomes for the patients with a lower expression of DNA repair enzymes.

This retrospective analysis will help establish further hypotheses. The role of DNA repair enzymes needs further investigation but does suggest a possible connection between low levels of the marker and resistance to platinum based or radiation therapy.

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD